var title_f10_51_11056="Hb Constant Spring and mRNA";
var content_f10_51_11056=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F66545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F66545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 588px\">",
"   <div class=\"ttl\">",
"    Alpha-globin mRNA instability in hemoglobin constant spring",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 568px; height: 425px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    As shown in the top panel of this figure, the synthesis of alpha globin mRNA and the levels of alpha-CP stabilizing proteins decline during the mid stages of erythroblast maturation. Because alpha-CP binding enhances stabilization of the Poly (A) 3' tail of mRNA by Poly (A) binding proteins, this leaves globin mRNA more susceptible to ribonuclease degradation in the late erythroblasts and circulating reticulocytes. This is illustrated in sections A and B of the lower panel for mRNA of normal alpha chains, which are stable in bone marrow precursors because of the binding of alpha-CP binding proteins (white oval with diagonal striping), and less stable in reticulocytes because of their absence. In red cell precursors in patients with the thalassemic hemoglobin Constant Spring, which contains a mutated termination codon, alpha-CP binding is blocked by ribosomal \"readthrough\" through the normally untranslated 3' Poly (A) tail region, which contains the alpha-CP binding sites (section C). This renders alpha chain (Constant Spring) mRNA unstable in early erythroblasts and very unstable in reticulocytes (section D).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Morales, J, et al. J Biol Chem 1997; 272:6607. Copyright &copy; 1997 American Society for Biochemistry and Molecular Biology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_51_11056=[""].join("\n");
var outline_f10_51_11056=null;
var title_f10_51_11057="Rubella rash PI";
var content_f10_51_11057=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rubella rash",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 272px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rubella causes a red rash on the face and body. It is caused by infection with the rubella virus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Image from: Centers for Disease Control and Prevention.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_51_11057=[""].join("\n");
var outline_f10_51_11057=null;
var title_f10_51_11058="Patient information: Cast and splint care (The Basics)";
var content_f10_51_11058=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?39/25/40338\">",
"         Patient information: Ankle fracture (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/6/5219\">",
"         Patient information: Boxer&rsquo;s fracture (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/20/7491\">",
"         Patient information: Common wrist injuries (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/5/3155\">",
"         Patient information: Finger fracture (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/34/30243\">",
"         Patient information: Fractures (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/29/3539\">",
"         Patient information: Meniscal tear (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/22/355\">",
"         Patient information: Toe fracture (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?25/21/25937\">",
"         Patient information: Cast and splint care (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Cast and splint care (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/cast-and-splint-care-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H95781494\">",
"      <span class=\"h1\">",
"       Why do I have a cast or splint?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor gave you a cast or splint to treat your broken bone. The cast or splint will reduce your pain and protect your bone as it heals.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H95781501\">",
"      <span class=\"h1\">",
"       Why is it important to take care of a cast or splint?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to take care of a cast or splint so that the skin under the cast doesn&rsquo;t get hurt or infected.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H95781508\">",
"      <span class=\"h1\">",
"       Can I get my cast wet?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends on what kind of cast you have. Your doctor will tell you if you have a waterproof cast that can get wet. Otherwise, you should",
"      <strong>",
"       not",
"      </strong>",
"      get your cast wet.",
"     </p>",
"     <p>",
"      To keep your cast dry when you bathe, cover it with a plastic bag and tape the bag shut. Then keep your cast outside the tub or shower when you wash your body. Some people buy a waterproof cast cover to use when bathing. If you use a waterproof cast cover, it&rsquo;s still a good idea to keep your cast outside the tub or shower. These covers are not completely waterproof.",
"     </p>",
"     <p>",
"      If your cast gets wet, you can dry it with a hair dryer set to the cool setting. Do not use a warm or hot setting, because those settings can burn the skin. You can also use a vacuum cleaner that has a hose to help dry your cast. Put the hose next to your cast so that you suck wet air out of the cast.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H95781515\">",
"      <span class=\"h1\">",
"       What are other ways I can take care of my cast?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To take care of your cast, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Keep your cast clean and avoid getting dirt or sand inside it",
"       </li>",
"       <li>",
"        Not put anything inside your cast",
"       </li>",
"       <li>",
"        Not put powder or lotion on the skin near your cast",
"       </li>",
"       <li>",
"        Not pull the lining out from inside the cast",
"       </li>",
"       <li>",
"        Cover your cast when you eat, so that it doesn&rsquo;t get dirty",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H95781522\">",
"      <span class=\"h1\">",
"       What if I have pain under my cast during the first few days?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have pain during the first few days, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Put ice on the cast &mdash; Use a bag of ice, bag of frozen peas, or cold gel pack every 1 to 2 hours, for 15 minutes each time. Put a thin towel between the ice (or other cold object) and your skin.",
"       </li>",
"       <li>",
"        Keep your cast raised (for example, on pillows) to help reduce swelling &mdash; To reduce swelling and pain, your cast needs to be raised above the level of your heart.",
"       </li>",
"       <li>",
"        Take medicine to relieve your pain &mdash; If your doctor prescribed pain-relieving medicine, you can take that. You can also ask your doctor or nurse about taking over-the-counter medicines, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (sample brand name: Tylenol&reg;) or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H95781529\">",
"      <span class=\"h1\">",
"       What if the skin under my cast itches?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your skin itches, you can use a hair dryer set to the cool setting to blow air inside the cast. Do not put anything in your cast to scratch the skin.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H95781536\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse right away if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You have severe pain or pain that is getting worse",
"       </li>",
"       <li>",
"        You have sores or cuts on the skin under the cast",
"       </li>",
"       <li>",
"        Your cast smells bad, feels too tight, or cracks",
"       </li>",
"       <li>",
"        You have swelling that causes pain",
"       </li>",
"       <li>",
"        You are unable to move your fingers or toes",
"       </li>",
"       <li>",
"        Your fingers or toes are blue or cold",
"       </li>",
"       <li>",
"        Your cast becomes soaking wet or you are unable to dry it",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H95781543\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30243?source=see_link\">",
"       Patient information: Fractures (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/20/7491?source=see_link\">",
"       Patient information: Common wrist injuries (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/5/3155?source=see_link\">",
"       Patient information: Finger fracture (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/25/40338?source=see_link\">",
"       Patient information: Ankle fracture (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/6/5219?source=see_link\">",
"       Patient information: Boxer&rsquo;s fracture (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/29/3539?source=see_link\">",
"       Patient information: Meniscal tear (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/22/355?source=see_link\">",
"       Patient information: Toe fracture (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=see_link\">",
"       Patient information: Cast and splint care (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?10/51/11058?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16196 Version 8.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-201.211.0.116-90250CA9DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_51_11058=[""].join("\n");
var outline_f10_51_11058=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95781494\">",
"      Why do I have a cast or splint?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95781501\">",
"      Why is it important to take care of a cast or splint?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95781508\">",
"      Can I get my cast wet?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95781515\">",
"      What are other ways I can take care of my cast?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95781522\">",
"      What if I have pain under my cast during the first few days?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95781529\">",
"      What if the skin under my cast itches?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95781536\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95781543\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/25/40338?source=related_link\">",
"      Patient information: Ankle fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/6/5219?source=related_link\">",
"      Patient information: Boxer&rsquo;s fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=related_link\">",
"      Patient information: Cast and splint care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/20/7491?source=related_link\">",
"      Patient information: Common wrist injuries (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/5/3155?source=related_link\">",
"      Patient information: Finger fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30243?source=related_link\">",
"      Patient information: Fractures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/29/3539?source=related_link\">",
"      Patient information: Meniscal tear (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/22/355?source=related_link\">",
"      Patient information: Toe fracture (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_51_11059="PSC liver US";
var content_f10_51_11059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81306%7EGAST%2F81312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81306%7EGAST%2F81312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary sclerosing cholangitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 298px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound image in a patient with primary sclerosing cholangitis shows dilation of segmental ducts (large arrows) and debris within the lumen of intrahepatic ducts (small arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Extrahepatic primary sclerosing cholangitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 296px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound image of the right upper quadrant in a patient with ulcerative colitis and primary sclerosing cholangitis shows marked thickening of the wall of the common bile duct (large arrows) and narrowing of its lumen (small arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_51_11059=[""].join("\n");
var outline_f10_51_11059=null;
var title_f10_51_11060="Antipyrine and benzocaine: Drug information";
var content_f10_51_11060=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Antipyrine and benzocaine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/61/42963?source=see_link\">",
"    see \"Antipyrine and benzocaine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/11/14514?source=see_link\">",
"    see \"Antipyrine and benzocaine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15070561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aurodex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F135881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Auralgan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F135890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Otic Agent, Analgesic;",
"     </li>",
"     <li>",
"      Otic Agent, Cerumenolytic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F135882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pain and swelling associated with otitis media:",
"     </b>",
"     Otic: Fill ear canal with solution; moisten cotton pledget with antipyrine and benzocaine solution, place in external ear, repeat every 1-2 hours until pain and congestion are relieved",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ear wax removal:",
"     </b>",
"     Otic: Instill drops 3 times/day for 2-3 days; before and after ear wax removal, moisten cotton pledget with antipyrine and benzocaine solution and place in external ear after solution instillation.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F135887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/11/14514?source=see_link\">",
"      see \"Antipyrine and benzocaine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F135883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15673196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15673197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F135872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, otic [drops]: Antipyrine 5.4% and benzocaine 1.4% (10 mL, 15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aurodex&trade;: Antipyrine 5.4% and benzocaine 1.4% (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F135862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F135874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Otic: Patient should lie down with affected ear upward and medication instilled; remain in the position to allow penetration of solution. Avoid touching dropper to ears or fingers. Do not rinse dropper after use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Otitis media: Fill ear canal with antipyrine and benzocaine solution. Moisten cotton pledget with solution and place in external ear.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ear wax removal:  Moisten cotton pledget with antipyrine and benzocaine solution and place in external ear after solution instillation.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F135873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of pain and reduction of swelling associated with acute congestive and serous otitis media; facilitates ear wax removal",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F135889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adverse reactions are reported in the manufacturer&rsquo;s labeling. Refer to Benzocaine monograph.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5093461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to antipyrine, benzocaine, or any component of the formulation; perforated tympanic membrane; ear discharge",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5093462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Irritation: Discontinue if sensitization or irritation occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Methemoglobinemia: Rare with combination product; has been reported with some topical products containing higher concentrations (14% to 20%) of benzocaine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For otic use only, do not apply to eyes.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F135868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5093459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5093460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F135877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Antipyrine-Benzocaine Otic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5.4-1.4% (10 mL): $11.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     54-14 mg/mL (15 mL): $12.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Auralgan Otic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5.5-1.4% (14 mL): $237.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Aurodex Otic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5.4-1.4% (10 mL): $11.37",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Auralgan (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, NZ, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Auralgan (non-prescription) (AU);",
"     </li>",
"     <li>",
"      Auralyt (CO);",
"     </li>",
"     <li>",
"      Otodyne (EC);",
"     </li>",
"     <li>",
"      Otogesic (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5093467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antipyrine has analgesic properties; benzocaine is a local anesthetic; the glycerin base provides decreased middle ear pressure by osmosis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5093469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Pain relief: ~30 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hoberman A, Paradise JL, Reynolds EA, et al, &ldquo;Efficacy of Auralgan for Treating Ear Pain in Children With Acute Otitis Media,&rdquo;",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 1997, 151(7):675-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/51/11060/abstract-text/9232040/pubmed\" id=\"9232040\" target=\"_blank\">",
"        9232040",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodriguez LF, Smolik LM, and Zbehlik AJ, &ldquo;Benzocaine-Induced Methemoglobinemia: Report of a Severe Reaction and Review of the Literature,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1994, 28(5):643-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/51/11060/abstract-text/8069004/pubmed\" id=\"8069004\" target=\"_blank\">",
"        8069004",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9189 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-1AFF26D322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_51_11060=[""].join("\n");
var outline_f10_51_11060=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15070561\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135881\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135890\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135882\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135887\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135883\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673196\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673197\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135872\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135862\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135874\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135873\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135889\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5093461\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5093462\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298761\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218031\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135868\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5093459\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5093460\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135877\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038530\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5093467\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5093469\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9189\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9189|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/61/42963?source=related_link\">",
"      Antipyrine and benzocaine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/11/14514?source=related_link\">",
"      Antipyrine and benzocaine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_51_11061="Directed (designated) blood donation programs";
var content_f10_51_11061=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Directed (designated) blood donation programs",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/51/11061/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/51/11061/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/51/11061/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/51/11061/contributors\">",
"     Steven Kleinman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/51/11061/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/51/11061/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/51/11061/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to 1983, recipient-specific donations were considered medically indicated in a limited number of clinical situations. These included pre-renal transplant sensitization regimens; HLA-matched or family member apheresis-harvested platelet concentrates for refractory, thrombocytopenic patients; and washed maternal platelets for infants with isoimmune neonatal thrombocytopenia.",
"   </p>",
"   <p>",
"    In direct response to concerns about blood safety raised by the AIDS epidemic, directed donations increased dramatically after 1985, despite official discouragement by all of the major blood banking organizations. Currently, directed donations constitute less than 1 percent of all blood collected, a figure that seems to be stable. While any blood component (red blood cells, plasma, cryoprecipitate, platelets or granulocytes) can be directed towards a particular patient, the vast majority of directed donations are for red blood cells.",
"   </p>",
"   <p>",
"    This topic covers issues specifically related to directed blood donation. The safety of blood donation for the donor, and the risks and benefits of any blood transfusion are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26106?source=see_link\">",
"       \"Procedures used for blood donor screening: Protection of potential blood donors and recipients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11672?source=see_link\">",
"       \"Administration and complications of red cell transfusion in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9048?source=see_link\">",
"       \"Red blood cell transfusions in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SAFETY OF DIRECTED BLOOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much of the early reluctance to provide directed donations, which centered on administrative and logistical concerns, has been overcome as directed donation programs are now no more complex to administer than are autologous transfusion programs. More substantive concerns about the relative safety of directed donor blood as compared with community, volunteer blood are now addressable with data accumulated by the Retrovirus Epidemiology Donor Studies (REDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11061/abstract/1\">",
"     1",
"    </a>",
"    ]. These data were collected at five geographically and demographically diverse blood centers under the sponsorship of the National Heart, Lung, and Blood Institute of the National Institutes of Health. Seropositivity for various infectious disease markers was measured in 30,778 first-time directed donors and compared with 384,276 first-time (allogeneic) community donors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were no significant differences in the prevalence of three of the five markers: anti-HIV-1 and HIV-2, anti-HCV, and a serologic test for syphilis (STS).",
"     </li>",
"     <li>",
"      Directed donors had a significantly higher prevalence of positive tests for anti-HTLV-I (relative risk 2.32) and HBsAg (relative risk 1.99).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further analysis of the REDS data indicated that essentially all differences between directed and community donors were explained by differences in the demographics of the two groups (age, sex, ethnic group, etc). The authors concluded that directed donors were no less safe simply because they were donating specifically for a friend or relative. Previous data comparing the prevalence of positive tests in directed donors (60 to 70 percent of whom were first-time donors) to community, volunteer donors (a much lower percentage of whom were first-time donors) were flawed because of the incomparability of the two groups.",
"   </p>",
"   <p>",
"    In summary, blood from directed donors is neither safer nor measurably less safe than blood from community, volunteer donors. Furthermore, there is an increased administrative cost associated with this procedure. As a result, we do",
"    <strong>",
"     not",
"    </strong>",
"    generally recommend directed donation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Directed donation and pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is probably true that some directed donors are safer than community donors, particularly spouses. However, it is prudent to avoid using a man&rsquo;s blood for his female partner if she is capable of and desirous of bearing children. In this setting, the woman may become sensitized to her partner&rsquo;s red cell or platelet antigens, possibly leading to hemolytic disease or thrombocytopenia in the newborn if the fetus and father have red cell or platelet antigens lacking in the mother. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=see_link&amp;anchor=H7#H7\">",
"     \"Neonatal thrombocytopenia\", section on 'Neonatal alloimmune thrombocytopenia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10665?source=see_link&amp;anchor=H2#H2\">",
"     \"Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn\", section on 'Types of hdn'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TECHNICAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H938919\">",
"    <span class=\"h2\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's physician should be responsible for requesting directed donations and should be kept informed as to the status of all blood collected. Designated donors, as well as the intended recipient, should be completely informed regarding the details of the directed donor program, particularly such issues as confidentiality, potential risks and benefits, and possible use of the blood for other than the intended recipient (if necessary). Informed consent should be obtained, preferably from both donor and recipient.",
"   </p>",
"   <p>",
"    Each institution offering directed donations should determine whether or not it is willing, prior to collecting the blood, to perform red cell typing of potential directed donors to determine if the blood is compatible with the recipient. Given a number of logistical and cost concerns, most community blood centers discourage this practice.",
"   </p>",
"   <p>",
"    Designated donors should meet all the criteria for protection of the recipient that are used for community, volunteer donors. This includes the fact that blood collected from these individuals is subjected to the same battery of infectious disease tests used to screen volunteer blood. With exceedingly rare exceptions (perhaps when a parent is donating for",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    child and has a non-significant positive viral marker such as anti-HBc), directed donor blood that has a positive infectious disease screening test is discarded. Because of this careful screening, the blood that is not required by the intended recipient can be made available for others. Crossover of directed donor blood is common practice, unlike autologous blood, although there are some collection facilities that discard unused directed donor blood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31605?source=see_link&amp;anchor=H5#H5\">",
"     \"Controversial areas in preoperative autologous blood donation\", section on 'Crossover (release to other recipients)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Frequency of donation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with allogeneic donors, directed donors should be restricted to donation schedules that meet Food and Drug Administration and AABB guidelines in which there are at least eight weeks between whole blood donations. Compressed schedules, appropriate for autologous donors, are generally not applicable to directed donors. One potential exception occurs when, in the opinion of the medical director, a component of truly enhanced safety can be provided by the designated donor (as with parent to infant or HLA-matched sibling to sibling). With repeated transfusion from a parent to an infant, for example, small quantities of relatively fresh blood are required at stable intervals. In this setting, it may be prudent to draw less than full units at shorter intervals than the current eight-week standard. This approach is recommended because it protects the donor from iron depletion and the recipient from exposure to multiple donors.",
"   </p>",
"   <p>",
"    With the establishment of newer, automated technology, directed donors can, if otherwise eligible based on (gender-specific) body size, donate dual red blood cell units, thereby doubling the contribution of red blood cells from a donor without the need for a compressed donation schedule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Dedicated donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The compelling argument that reducing donor exposure enhances transfusion safety has encouraged some to suggest a new classification of donor that is a variation of a directed donor, a so-called \"dedicated\" donor [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11061/abstract/2\">",
"     2",
"    </a>",
"    ]. Dedicated donors are committed to providing repeated donations of specific components for a single recipient, thereby reducing or obviating the need for that patient to receive components from multiple donors. While no allowances have been made in the standards for blood banking and transfusion medicine published by the AABB to enable dedicated donors to donate more frequently, this regimen is gaining in popularity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Directed donor blood cannot be used for emergency transfusion, given the need to collect and test the blood. With exceedingly rare exceptions, directed donor blood should not be made available for transfusion until completely tested. Since complete testing usually takes approximately 48 hours (and one should also factor in time for paperwork, delivery of the blood to the hospital, and perhaps time to seek a replacement donor should the first donor be disqualified for any reason), it would make sense to have directed donors&rsquo; blood drawn approximately one week prior to the scheduled surgical procedure. If everything were to work to perfection, and the primary intended donor&rsquo;s blood be made available for transfusion, 48 to 72 hours would be the shortest time frame in which this could occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     BLOOD IRRADIATION WITH RELATED DONORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1989, attention was drawn to one of the potential adverse consequences of receiving blood from related donors: development of often fatal transfusion-associated graft-versus-host disease (ta-GVHD) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11061/abstract/3\">",
"     3",
"    </a>",
"    ]. This can occur in fully immunocompetent individuals, and it is most likely to occur when the donor is homozygous for an HLA haplotype shared with the recipient. Subsequent reports confirmed this relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11061/abstract/4-6\">",
"     4-6",
"    </a>",
"    ], prompting the AABB to require irradiation of all donor units drawn from a blood relative of the intended recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11061/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=see_link\">",
"     \"Transfusion-associated graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/52/22338?source=see_link\">",
"       \"Patient information: Blood donation (giving blood) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/12/26820?source=see_link\">",
"       \"Patient information: Blood donation and transfusion (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16974621\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In direct response to concerns about blood safety raised by the AIDS epidemic, directed donations increased dramatically after 1985, despite official discouragement by all of the major blood banking organizations. Problem areas include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Safety and cost issues",
"      </strong>",
"      &ndash; Blood from directed donors is neither safer nor measurably less safe than blood from community, volunteer donors. There is an increased administrative cost associated with this procedure.",
"     </li>",
"     <li>",
"      <strong>",
"       Pregnancy",
"      </strong>",
"      &ndash; It is prudent to avoid using a man&rsquo;s blood for his female partner if she is capable of and desirous of bearing children, as she may become sensitized to his red cell or platelet antigens, possibly leading to hemolytic disease or thrombocytopenia in the newborn. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Directed donation and pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Donor eligibility",
"      </strong>",
"      &ndash; Designated donors should meet all the criteria for protection of the recipient that are used for community, volunteer donors. By so doing, the blood that is not required by the intended recipient can be made available for others.",
"     </li>",
"     <li>",
"      <strong>",
"       Need for blood irradiation if donor is related",
"      </strong>",
"      &ndash; One of the potential adverse consequences of receiving blood from related donors is the development of fatal transfusion-related graft-versus-host disease. Accordingly, the AABB requires irradiation of all donor units drawn from a blood relative of the intended recipient. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Blood irradiation with related donors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=see_link\">",
"       \"Transfusion-associated graft-versus-host disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11061/abstract/1\">",
"      Williams AE, Kleinman S, Gilcher RO, et al. The prevalence of infectious disease markers in directed vs homologous blood donations (abstract). Transfusion 1992; 32:45S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11061/abstract/2\">",
"      Strauss RG, Wieland MR, Randels MJ, Koerner TA. Feasibility and success of a single-donor red cell program for pediatric elective surgery patients. Transfusion 1992; 32:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11061/abstract/3\">",
"      Juji T, Takahashi K, Shibata Y, et al. Post-transfusion graft-versus-host disease in immunocompetent patients after cardiac surgery in Japan. N Engl J Med 1989; 321:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11061/abstract/4\">",
"      Petz LD, Calhoun L, Yam P, et al. Transfusion-associated graft-versus-host disease in immunocompetent patients: report of a fatal case associated with transfusion of blood from a second-degree relative, and a survey of predisposing factors. Transfusion 1993; 33:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11061/abstract/5\">",
"      Kanter MH. Transfusion-associated graft-versus-host disease: do transfusions from second-degree relatives pose a greater risk than those from first-degree relatives? Transfusion 1992; 32:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11061/abstract/6\">",
"      Perkins HA. Should all blood from related donors be irradiated? Transfusion 1992; 32:302.",
"     </a>",
"    </li>",
"    <li>",
"     Klein HG (Ed). Standards for blood banks and transfusion services, 16th ed, American Association of Blood Banks, Bethesda, 1994.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7934 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-5088ACF45B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_51_11061=[""].join("\n");
var outline_f10_51_11061=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16974621\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SAFETY OF DIRECTED BLOOD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Directed donation and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TECHNICAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H938919\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Frequency of donation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Dedicated donors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      BLOOD IRRADIATION WITH RELATED DONORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16974621\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11672?source=related_link\">",
"      Administration and complications of red cell transfusion in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31605?source=related_link\">",
"      Controversial areas in preoperative autologous blood donation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=related_link\">",
"      Neonatal thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/52/22338?source=related_link\">",
"      Patient information: Blood donation (giving blood) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/12/26820?source=related_link\">",
"      Patient information: Blood donation and transfusion (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10665?source=related_link\">",
"      Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26106?source=related_link\">",
"      Procedures used for blood donor screening: Protection of potential blood donors and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9048?source=related_link\">",
"      Red blood cell transfusions in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=related_link\">",
"      Transfusion-associated graft-versus-host disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_51_11062="Cervical pregnancy";
var content_f10_51_11062=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cervical pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/51/11062/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/51/11062/contributors\">",
"     Togas Tulandi, MD, MHCM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/51/11062/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/51/11062/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/51/11062/contributors\">",
"     William J Mann, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/51/11062/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/51/11062/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/51/11062/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical pregnancy is a rare form of ectopic pregnancy in which the pregnancy implants in the lining of the endocervical canal. It accounts for less than 1 percent of ectopic pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The incidence is approximately 1 in 9000 deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Cervical pregnancy may be more common in pregnancies achieved through assisted reproductive technologies; it occurs in 0.1 percent of in vitro fertilization pregnancies and accounts for 3.7 percent of IVF ectopic gestations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cause is unknown; local pathology related to previous cervical or uterine surgery may play a role given an apparent association with a prior history of curettage or cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Another theory is rapid transport of the fertilized ovum into the endocervical canal before it is capable of nidation or because of an unreceptive endometrium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common symptom of cervical pregnancy is vaginal bleeding, which is often profuse and painless [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Lower abdominal pain or cramps occur in fewer than one-third of patients; pain without bleeding is rare. It is important to think about the possibility of cervical pregnancy in such patients since early diagnosis is critical to avoidance of complications and successful treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general approach to evaluation of pregnant women with first trimester bleeding is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15465?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the etiology and evaluation of vaginal bleeding in pregnant women\", section on 'First trimester bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On speculum examination, the external os may be open, revealing fetal membranes or pregnancy tissue, which appear blue or purple. Infrequently, a cystic lesion on the cervical lip is observed and represents trophoblastic invasion into the cervical stroma.",
"   </p>",
"   <p>",
"    Ideally, if cervical pregnancy is suspected, bimanual examination is avoided until imaging studies have excluded the diagnosis (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Diagnosis'",
"    </a>",
"    below). If bimanual examination is performed, the endocervical canal should not be explored as this is likely to cause hemorrhage. A prominent finding on bimanual examination of cervical pregnancy is a soft cervix that is disproportionately enlarged compared to the uterus; this has been called \"an hour-glass\" shaped uterus [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/3\">",
"     3",
"    </a>",
"    ]. By comparison, enlargement of the uterus without significant cervical enlargement is characteristic of intrauterine pregnancy, although the cervix softens and becomes mildly congested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a woman with a positive pregnancy test, the clinical diagnosis of cervical pregnancy is based upon findings on transvaginal ultrasound examination [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/3,6-8\">",
"     3,6-8",
"    </a>",
"    ]. A correct diagnosis is important to avoid interventions which could lead to severe hemorrhage necessitating hysterectomy.",
"   </p>",
"   <p>",
"    Sonographic criteria for diagnosis of cervical pregnancy consist of [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      gestational sac or placenta within the cervix (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57961 \" href=\"UTD.htm?31/29/32214\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      normal endometrial stripe",
"     </li>",
"     <li>",
"      hourglass (figure of eight) shaped uterus with ballooned cervical canal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional signs include visualization of an embryo or fetus in the intracervical area and gestational sac below the level of the internal cervical os or uterine arteries. A sonographic impression of cervical pregnancy is correct in 87.5 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main differential consideration for cervical ectopic pregnancy is an incomplete abortion that is proximal to the cervix. Typical features that differentiate a cervical pregnancy from an incomplete abortion include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      cardiac activity is often seen in a cervical pregnancy with a visible embryo, but not in an incomplete abortion [",
"      <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      the gestational sac of a cervical pregnancy has regular contours, while an incomplete abortion sac often has irregular contours that may change shape during the scan",
"     </li>",
"     <li>",
"      the cervical os is typically closed in a cervical pregnancy, but is open in an incomplete abortion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Magnetic resonance imaging can be helpful in unusual or complicated cases when the diagnosis is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rubin defined histologic criteria for cervical pregnancy, but a histologic diagnosis is not clinically practical since it requires hysterectomy. Rubin's criteria consist of: close attachment of the placenta to the cervix, cervical glands present opposite the implantation site, placental location below uterine vessel insertion or below anterior and posterior reflections of the visceral peritoneum of the uterus, and no fetal elements in the uterine corpus [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term cervical abortion has been used to describe an aborting intrauterine pregnancy that is trapped in the endocervical canal because of resistance from the external cervical os. An intrauterine pregnancy in the process of aborting can mimic a cervical pregnancy if the products of conception have not passed through the external cervical os. This diagnosis is likely if ultrasound reveals some products of",
"    <span class=\"nowrap\">",
"     conception/blood",
"    </span>",
"    clot in the uterine cavity, the uterine cavity is enlarged compared to the cervix, the internal cervical os is open, or the gestational sac is flattened and has no or a minimal echogenic rim and contains no or a dead embryo [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. In addition, a cervical abortion should not show any signs of trophoblastic invading the cervical stroma or cardiac activity; the presence of intracervical peritrophoblastic blood flow by",
"    <span class=\"nowrap\">",
"     color/pulsed",
"    </span>",
"    Doppler ultrasound or cardiac activity suggests a true cervical pregnancy. Cervical pregnancy rather than incomplete abortion is also suggested by a negative sliding sac sign: no movement of the intracervical sac when the vaginal transducer is used to apply gentle pressure to the cervix.",
"   </p>",
"   <p>",
"    If the diagnosis is uncertain, repeating the ultrasound the next day to see if the sac has moved (suggestive of a cervical abortion) or performing magnetic resonance imaging can help clarify the diagnosis.",
"   </p>",
"   <p>",
"    Differential diagnosis also includes cesarean or hysterotomy scar pregnancy, which should be considered if the gestational sac is in the anterior lower uterine segment and the uterine cavity and endocervical canal are empty [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We treat hemodynamically stable women with cervical pregnancy medically using multidose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) therapy with intraamniotic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intrafetal injection of local",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    (KCL) (eg, intracardiac injection of about 5 mEq potassium chloride) when fetal cardiac activity is present [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/15\">",
"     15",
"    </a>",
"    ]. This treatment results in ablation of the ectopic gestation and allows preservation of the uterus in at least 80 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/3\">",
"     3",
"    </a>",
"    ]. Diagnosis and treatment early in pregnancy are important since most cases of severe hemorrhage and need for hysterectomy have occurred in pregnancies in the late first and early second trimesters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Criteria have been proposed for selecting patients who are most likely to have a successful outcome from medical therapy of tubal ectopic pregnancy, as well those who should undergo a primary surgical approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27417?source=see_link&amp;anchor=H3#H3\">",
"     \"Methotrexate treatment of tubal and interstitial ectopic pregnancy\", section on 'Candidates for medical treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, there are no criteria for selecting appropriate candidates for medical treatment of cervical pregnancy, other than ensuring that the patient is hemodynamically stable. One reason for this difference is that experience with cervical pregnancy is too limited to allow any firm conclusions about optimal criteria for medical therapy. As an example, the presence of fetal cardiac activity (present in 60 percent of cervical pregnancies in contrast to 10 percent of tubal pregnancies) is a poor prognostic factor for successful medical therapy of tubal pregnancy, but whether this is also true for cervical pregnancy is not known. Another factor is that when weighing risks and benefits of medical versus surgical therapy, there is a higher tolerance for complications from medical therapy of cervical pregnancy compared to tubal pregnancy since the alternative, surgical therapy, carries a significant risk of hemorrhage when the pregnancy is cervical.",
"   </p>",
"   <p>",
"    Experience with use of MTX for treatment of cervical pregnancy is limited to case reports and small series [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/3,6,16-23\">",
"     3,6,16-23",
"    </a>",
"    ]. Various medical therapies have been used (single or multidose systemic MTX, local intrasac injection of MTX or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    , or combinations of these therapies) and were efficacious in 80 to 90 percent of cases. There were no complications other than the usual side effects of MTX therapy.",
"   </p>",
"   <p>",
"    Intramuscular multidose MTX alone is often adequate for treatment of very early cervical pregnancies without fetal cardiac activity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/24\">",
"     24",
"    </a>",
"    ]. We give MTX intramuscularly, rather than intravenously, as the intramuscular approach is more convenient and there are no data indicating that one route is superior to the other. The multidose MTX drug protocol is the same as that used in patients with tubal ectopic pregnancy and is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27417?source=see_link\">",
"     \"Methotrexate treatment of tubal and interstitial ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, more advanced gestations where fetal cardiac activity is present require combined treatment with both intramuscular multidose MTX and intraamniotic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intrafetal injection of KCL to cause prompt fetal death and thus facilitate pregnancy resorption, which can take a few months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. We perform intrasac injection in the operating room because there is a risk of hemorrhage when the sac collapses. A 20-22 gauge needle is advanced transvaginally into the gestational sac and fetal thorax under direct ultrasound visualization using a needle guide attachment. When the tip of the needle is in the embryo, KCL (1 to 5 mL of 20 percent KCL solution) is injected until there is cessation of cardiac activity.",
"   </p>",
"   <p>",
"    Heavy vaginal bleeding when the pregnancy is involuting may require intraarterial embolization to control hemorrhage. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Uterine artery embolization'",
"    </a>",
"    below.) If this is not successful, then dilation and evacuation is the next step; hysterectomy is a last resort. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Surgical therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional treatment of cervical pregnancy has been dilation and curettage, with hysterectomy if there is uncontrolled hemorrhage. However, we feel that avoidance of hysterectomy is desirable since it precludes further childbearing and is a major operation.",
"   </p>",
"   <p>",
"    Dilation and evacuation is a conservative surgical option. The main complication is a high incidence of severe hemorrhage, which can be reduced by preoperative measures such as transvaginal ligation of the cervical branches of the uterine arteries, Shirodkar cerclage, angiographic uterine artery embolization, or intracervical vasopressin injection. The latter is given by injecting 20 to 30 mL of vasopressin (0.5",
"    <span class=\"nowrap\">",
"     U/mL)",
"    </span>",
"    solution with a 1.5-inch 21 gauge needle circumferentially deep into the dense cervical stroma. Transvaginal ligation of the cervicovaginal branches of the uterine artery can be performed, as well. This is done by deviating the cervix to one side and placing a suture at 3 and 9 o'clock on the lateral side of the cervix. The suture is placed high just below the lateral vaginal fornix, similar to sutures placed for hemostasis during cold knife conization. We use 2-0 polyglactin (Vicryl) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. However, our preference is preoperative angiographic uterine artery embolization (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Uterine artery embolization'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    If postoperative implantation site bleeding occurs, it can often be controlled by placing a size 26 Foley catheter with a 30 mL balloon into the dilated cervix, with the tip extending into the uterine cavity. Sterile water (as much as 95 mL) is used to inflate the balloon and tamponade the bleeding vessels for 24 to 48 hours. A purse string suture can be placed around the external cervical os and tied after inflation of the balloon to prevent expulsion. After 24 to 48 hours, the balloon is gradually deflated over a period of hours to days and removed, but may be reinflated at any time if bleeding picks up or recurs. The catheter also allows constant uterine drainage.",
"   </p>",
"   <p>",
"    Additional measures that can be employed in women who continue to bleed include placement of hemostatic sutures locally in the cervix, angiographic embolization, bilateral internal iliac artery ligation, and bilateral uterine artery ligation. Hysteroscopic resection with a resectoscope has also been reported to be successful in one case [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42600?source=see_link\">",
"     \"Overview of postpartum hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hysterectomy is an option for women who have completed their families or have additional uterine pathology and do not want to assume the risk of hemorrhage, which can occur in the course of conservative surgery or medical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Uterine artery embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine artery embolization prior to evacuation of cervical pregnancy may be an effective method for preventing hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/3,23,29-31\">",
"     3,23,29-31",
"    </a>",
"    ]. In one small series, this approach was successful in avoiding hysterectomy or laparotomy in",
"    <span class=\"nowrap\">",
"     16/16",
"    </span>",
"    cases. By comparison, a literature review reported 71 percent of 41 cases treated without such preoperative preparation resulted in massive hemorrhage; seven cases ended in hysterectomy and five cases were treated with bilateral internal iliac or uterine artery ligation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/3\">",
"     3",
"    </a>",
"    ]. Uterine artery embolization can also be performed to control hemorrhage occurring postoperatively or in conjunction with medical therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30408?source=see_link\">",
"     \"Interventional radiology in management of gynecological disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gelfoam provides temporary obstruction (two to six weeks) of the feeding blood vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/6,19\">",
"     6,19",
"    </a>",
"    ] and allows for development of collateral blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/32\">",
"     32",
"    </a>",
"    ]. Because collateral flow begins to develop within hours of the procedure, surgical evacuation should be performed soon after embolization to achieve the full benefit of the procedure. The optimal interval between uterine artery embolization and surgical evacuation has not been established, intervals of several hours to 24 hours have been described.",
"   </p>",
"   <p>",
"    There have been no reports of a procedure-related ischemic effect on the uterus; however, reflux of embolic material to the posterior division of the hypogastric artery can cause claudication of the lower abdomen and buttocks, which is usually transient [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/3,32\">",
"     3,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although uterine artery embolization is a promising technique for reducing morbidity in women with cervical pregnancy, further investigation is required before this approach can be recommended routinely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PREGNANCY OUTCOME IN SUBSEQUENT GESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of 37 pregnancies two months to several years after a cervical pregnancy reported the following: 21 women delivered at term (including one set of twins at 38 weeks), four delivered prematurely (at 25, 28, 32, and 36 weeks of gestation), three miscarried at 8 to 9 weeks of gestation, two underwent elective pregnancy termination, two had tubal pregnancies, one had a repeat cervical pregnancy (pregnancy conceived by IVF), and four had ongoing pregnancies at the time of the report [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11062/abstract/3\">",
"     3",
"    </a>",
"    ]. Three women had a McDonald cerclage placed because of suspected cervical insufficiency,",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most effective treatment of cervical pregnancy is still unclear. Publications on this subject are limited to case reports with a small number of cases. The management described below is based on these publications and our own experience treating ectopic tubal and cervical pregnancies.",
"     </li>",
"     <li>",
"      We suggest medical rather than surgical therapy of cervical pregnancy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We administer multidose, systemic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      intramuscularly. If fetal cardiac activity is present, we also inject",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"       potassium chloride",
"      </a>",
"      into the gestational",
"      <span class=\"nowrap\">",
"       sac/embryo.",
"      </span>",
"     </li>",
"     <li>",
"      In patients who are hemodynamically unstable or choose surgical therapy, we suggest preoperative uterine arterial embolization followed by dilation and evacuation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If preoperative uterine arterial embolization is not available, we suggest ligation of the descending branch of the uterine artery prior to dilation and evacuation and placement of a balloon catheter to tamponade the implantation site after evacuation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Surgical therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/1\">",
"      Yankowitz J, Leake J, Huggins G, et al. Cervical ectopic pregnancy: review of the literature and report of a case treated by single-dose methotrexate therapy. Obstet Gynecol Surv 1990; 45:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/2\">",
"      Bouyer J, Coste J, Fernandez H, et al. Sites of ectopic pregnancy: a 10 year population-based study of 1800 cases. Hum Reprod 2002; 17:3224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/3\">",
"      Ushakov FB, Elchalal U, Aceman PJ, Schenker JG. Cervical pregnancy: past and future. Obstet Gynecol Surv 1997; 52:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/4\">",
"      Vela G, Tulandi T. Cervical pregnancy: the importance of early diagnosis and treatment. J Minim Invasive Gynecol 2007; 14:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/5\">",
"      Karande VC, Flood JT, Heard N, et al. Analysis of ectopic pregnancies resulting from in-vitro fertilization and embryo transfer. Hum Reprod 1991; 6:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/6\">",
"      Jurkovic D, Hacket E, Campbell S. Diagnosis and treatment of early cervical pregnancy: a review and a report of two cases treated conservatively. Ultrasound Obstet Gynecol 1996; 8:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/7\">",
"      Monteagudo A, Tarricone NJ, Timor-Tritsch IE, Lerner JP. Successful transvaginal ultrasound-guided puncture and injection of a cervical pregnancy in a patient with simultaneous intrauterine pregnancy and a history of a previous cervical pregnancy. Ultrasound Obstet Gynecol 1996; 8:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/8\">",
"      Hofmann HM, Urdl W, H&ouml;fler H, et al. Cervical pregnancy: case reports and current concepts in diagnosis and treatment. Arch Gynecol Obstet 1987; 241:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/9\">",
"      Kung FT, Lin H, Hsu TY, et al. Differential diagnosis of suspected cervical pregnancy and conservative treatment with the combination of laparoscopy-assisted uterine artery ligation and hysteroscopic endocervical resection. Fertil Steril 2004; 81:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/10\">",
"      Timor-Tritsch IE, Monteagudo A, Mandeville EO, et al. Successful management of viable cervical pregnancy by local injection of methotrexate guided by transvaginal ultrasonography. Am J Obstet Gynecol 1994; 170:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/11\">",
"      Jung SE, Byun JY, Lee JM, et al. Characteristic MR findings of cervical pregnancy. J Magn Reson Imaging 2001; 13:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/12\">",
"      Rubin IC. Cervical pregnancy. Surg Gynecol Obstet 1911; 13:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/13\">",
"      Wang YL, Su TH, Chen HS. Laparoscopic management of an ectopic pregnancy in a lower segment cesarean section scar: a review and case report. J Minim Invasive Gynecol 2005; 12:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/14\">",
"      Maymon R, Halperin R, Mendlovic S, et al. Ectopic pregnancies in a Caesarean scar: review of the medical approach to an iatrogenic complication. Hum Reprod Update 2004; 10:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/15\">",
"      Yao, M, Tulandi, T. Practical and current management of tubal and non-tubal ectopic pregnancies. Current Problems in Obstetrics, Gynecology and Fertility 2000; 23:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/16\">",
"      Hung TH, Jeng CJ, Yang YC, et al. Treatment of cervical pregnancy with methotrexate. Int J Gynaecol Obstet 1996; 53:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/17\">",
"      Qasim SM, Bohrer MK, Kemmann E. Recurrent cervical pregnancy after assisted reproduction by intrafallopian transfer. Obstet Gynecol 1996; 87:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/18\">",
"      Dotters DJ, Katz VL, Kuller JA, McCoy MC. Successful treatment of a cervical pregnancy with a single low dose methotrexate regimen. Eur J Obstet Gynecol Reprod Biol 1995; 60:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/19\">",
"      Sieck UV, Hollanders JM, Jaroudi KA, Al-Took S. Cervical pregnancy following ultrasound-guided embryo transfer. Methotrexate treatment in spite of high beta-HCG levels. Hum Reprod 1997; 12:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/20\">",
"      Mesogitis S, Pilalis A, Daskalakis G, et al. Management of early viable cervical pregnancy. BJOG 2005; 112:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/21\">",
"      Kirk E, Condous G, Haider Z, et al. The conservative management of cervical ectopic pregnancies. Ultrasound Obstet Gynecol 2006; 27:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/22\">",
"      Jeng CJ, Ko ML, Shen J. Transvaginal ultrasound-guided treatment of cervical pregnancy. Obstet Gynecol 2007; 109:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/23\">",
"      Hung TH, Shau WY, Hsieh TT, et al. Prognostic factors for an unsatisfactory primary methotrexate treatment of cervical pregnancy: a quantitative review. Hum Reprod 1998; 13:2636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/24\">",
"      Weibel HS, Alserri A, Reinhold C, Tulandi T. Multidose methotrexate treatment of cervical pregnancy. J Obstet Gynaecol Can 2012; 34:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/25\">",
"      Mitra AG, Harris-Owens M. Conservative medical management of advanced cervical ectopic pregnancies. Obstet Gynecol Surv 2000; 55:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/26\">",
"      Monteagudo A, Minior VK, Stephenson C, et al. Non-surgical management of live ectopic pregnancy with ultrasound-guided local injection: a case series. Ultrasound Obstet Gynecol 2005; 25:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/27\">",
"      Doubilet PM, Benson CB, Frates MC, Ginsburg E. Sonographically guided minimally invasive treatment of unusual ectopic pregnancies. J Ultrasound Med 2004; 23:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/28\">",
"      Ash S, Farrell SA. Hysteroscopic resection of a cervical ectopic pregnancy. Fertil Steril 1996; 66:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/29\">",
"      Yao, M, Tulandi, T. Practical and current management of tubal and non-tubal ectopic pregnancies. Curr Prob Obstet Gynecol Fertil 2000; 23:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/30\">",
"      Frates MC, Benson CB, Doubilet PM, et al. Cervical ectopic pregnancy: results of conservative treatment. Radiology 1994; 191:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/31\">",
"      Zakaria MA, Abdallah ME, Shavell VI, et al. Conservative management of cervical ectopic pregnancy: utility of uterine artery embolization. Fertil Steril 2011; 95:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11062/abstract/32\">",
"      Hansch E, Chitkara U, McAlpine J, et al. Pelvic arterial embolization for control of obstetric hemorrhage: a five-year experience. Am J Obstet Gynecol 1999; 180:1454.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3283 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-F1EFE81ED1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_51_11062=[""].join("\n");
var outline_f10_51_11062=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Uterine artery embolization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PREGNANCY OUTCOME IN SUBSEQUENT GESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3283\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3283|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/29/32214\" title=\"diagnostic image 1\">",
"      Cervical pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30408?source=related_link\">",
"      Interventional radiology in management of gynecological disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27417?source=related_link\">",
"      Methotrexate treatment of tubal and interstitial ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42600?source=related_link\">",
"      Overview of postpartum hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15465?source=related_link\">",
"      Overview of the etiology and evaluation of vaginal bleeding in pregnant women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_51_11063="CRS Pathophysiology";
var content_f10_51_11063=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Pathophysiology of cardiorenal syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 700px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ACEI: angiotensin converting enzyme inhbitor; ARBs: angiotensin II receptor blockers; CO: cardiac output; CVP: central venous pressure; LVEDP: left ventricular end-diastolic pressure; ETs: endothelins; NO: nitric oxide; NP: natriuretic peptides; NSAIDs: nonsteroidal antiinflammatory drugs; RAAS: renal angiotenin aldosterone system; SNS: sympathetic nervous system; SV: stroke volume.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_51_11063=[""].join("\n");
var outline_f10_51_11063=null;
var title_f10_51_11064="CDC weight for age boys 2 to 20 years";
var content_f10_51_11064=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71721%7EPEDS%2F53325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71721%7EPEDS%2F53325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 586px\">",
"   <div class=\"ttl\">",
"    Weight-for-age percentiles, boys, 2 to 20 years, CDC growth charts: United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 566px; height: 688px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: National Health Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Weight-for-age percentiles, girls, 2 to 20 years, CDC growth charts: United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 689px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: National Health Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_51_11064=[""].join("\n");
var outline_f10_51_11064=null;
var title_f10_51_11065="RB-ILD histology";
var content_f10_51_11065=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Respiratory bronchiolitis in patient with respiratory bronchiolitis-associated interstitial lung disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 411px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Faintly pigmented alveolar macrophages fill the lumen of this respiratory bronchiole and the surrounding airspaces. There is a mild thickening of the wall of the respiratory bronchiole.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_51_11065=[""].join("\n");
var outline_f10_51_11065=null;
var title_f10_51_11066="Adjuvant therapy for resected colon cancer in elderly patients";
var content_f10_51_11066=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adjuvant therapy for resected colon cancer in elderly patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/51/11066/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/51/11066/contributors\">",
"     Hanna K Sanoff, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/51/11066/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/51/11066/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/51/11066/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/51/11066/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/51/11066/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 142,820 new cases of large bowel cancer are diagnosed each year in the United States, of which 102,480 are colon cancers; the remainder arise in the rectum [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/1\">",
"     1",
"    </a>",
"    ]. Global, country-specific incidence rates for colorectal cancer are available through the World Health Organization",
"    <a class=\"external\" href=\"file://globocan.iarc.fr/\">",
"     GLOBOCAN database",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Age is a major risk factor for colorectal cancer (",
"    <a class=\"graphic graphic_figure graphicRef76495 \" href=\"UTD.htm?12/1/12318\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/2\">",
"     2",
"    </a>",
"    ]. The median age at diagnosis is 71. Approximately 70 percent of cases develop over the age of 65; 40 percent are 75 years or older. The US Census bureau projects that by the year 2030 the number of Americans over age 65 will double [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/3\">",
"     3",
"    </a>",
"    ]. As a result, the number of patients over the age of 70 presenting for colorectal cancer care is expected to rise.",
"   </p>",
"   <p>",
"    Surgical resection is the only curative treatment for locoregional colon cancer, and outcome is most closely related to the extent of disease at presentation (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef81414 \" href=\"UTD.htm?40/54/41824\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/4\">",
"     4",
"    </a>",
"    ]. For patients who have undergone potentially curative resection, disease recurrence is thought to arise from clinically occult micrometastases that are present at the time of surgery. Postoperative (adjuvant) systemic chemotherapy is recommended for high-risk patients to eradicate these micrometastases, thereby increasing the cure rate.",
"   </p>",
"   <p>",
"    This topic review will cover the benefits, risks, and choice of adjuvant chemotherapy for elderly patients with resected colon cancer. A general discussion of the benefits of adjuvant chemotherapy for resected colon and rectal cancer, surgical management and prognosis of colon cancer, chemotherapy considerations in older individuals with advanced colorectal cancer, a compilation of chemotherapy protocols for colorectal cancer, and recommendations for posttreatment follow-up are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4922?source=see_link\">",
"     \"Adjuvant therapy for resected rectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30489?source=see_link\">",
"     \"Overview of the management of primary colon cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41466?source=see_link\">",
"     \"Therapy for metastatic colorectal cancer in elderly patients and those with a poor performance status\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28634?source=see_link\">",
"     \"Surveillance after colorectal cancer resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHALLENGES SPECIFIC TO THE ELDERLY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The essential principles of treating colon cancer in the elderly are the same as in younger patients. However, for older patients, who may have age-related organ function decline and comorbid conditions that may limit life expectancy, special attention must be paid to the risks of chemotherapy, including both treatment-related toxicity and quality of life issues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Age-related organ function decline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aging is commonly accompanied by a decline in the function of critical organ system [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=see_link&amp;anchor=H2#H2\">",
"     \"Systemic chemotherapy for cancer in elderly persons\", section on 'Challenges specific to elderly patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This has several implications for elderly patients undergoing adjuvant chemotherapy for colon cancer (",
"    <a class=\"graphic graphic_table graphicRef57349 \" href=\"UTD.htm?21/61/22491\">",
"     table 2",
"    </a>",
"    ). As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Liver/renal",
"      </span>",
"      function &ndash; Declining liver and kidney function with age can alter cancer drug metabolism and elimination. Of the drugs commonly used in the adjuvant setting to treat colon cancer, only",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      is predominately cleared by the kidney. A 25 percent dose reduction is recommended for patients who have an estimated GFR of 30 to 50",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      and the drug should be avoided if the estimated GFR is &lt;30",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=see_link&amp;anchor=H20#H20\">",
"       \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'Capecitabine'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, liver",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    kidney disease places patients at an increased risk for a non-colon cancer-related death [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Comorbid conditions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiovascular &ndash; Normal aging is associated with an increased risk of coronary artery disease. Among patients undergoing adjuvant chemotherapy for colon cancer, the possibility of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      -induced vasospasm should be considered in patients who develop chest pain or otherwise unexplained decompensated heart failure during treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=see_link&amp;anchor=H2#H2\">",
"       \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\", section on 'Antimetabolites'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bone marrow reserve &ndash; Bone marrow reserve diminishes as a part of normal aging, placing older patients at greater risk for severe and prolonged chemotherapy-related cytopenias. Chemotherapy dose reduction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      delay may be necessary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another alternative is the use of hematopoietic growth factor support during treatment. However, there is no role for primary prophylaxis with myeloid growth factors. Guidelines from the American Society of Clinical Oncology (ASCO) support primary prophylaxis with myeloid growth factors only for chemotherapy regimens that have a risk of febrile neutropenia &ge;20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/8\">",
"     8",
"    </a>",
"    ]. None of the commonly used chemotherapy regimens used for adjuvant treatment of colon cancer meet this criterion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link&amp;anchor=H523774212#H523774212\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\", section on 'Primary prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Comorbid conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients over the age of 75 have an average of five other medical conditions at the time of diagnosis of colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. The most common are anemia (often from occult blood loss related to a primary colon cancer), hypertension, other gastrointestinal diagnoses, and heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/7\">",
"     7",
"    </a>",
"    ]. Of these, liver and kidney disease place patients at greatest risk of noncancer-related death [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients undergoing surgery for colon cancer, severe comorbidity increases the complexity of cancer management, and it decreases both overall and cancer-specific survival (",
"    <a class=\"graphic graphic_table graphicRef79620 \" href=\"UTD.htm?38/63/39932\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For seriously ill patients with severe comorbid illness that diminishes life expectancy (particularly to one year or less), the risks of adjuvant chemotherapy for colon cancer may outweigh its benefits. On the other hand, for patients who have multiple but not life-threatening comorbid conditions, the benefits of adjuvant therapy appear to be preserved without an increased risk of severe chemotherapy toxicity or hospitalization during adjuvant therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several comorbidity indices are available, and all appear useful for predicting which patients are likely to have lower levels of overall and cancer-specific survival after colon cancer surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/11\">",
"     11",
"    </a>",
"    ]. One such tool, the Charlson comorbidity index (CCI), is outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef72047 \" href=\"UTD.htm?25/40/26252\">",
"     table 4",
"    </a>",
"    ). In one series, patients with a CCI of &ge;3 had a significant twofold higher risk of colon cancer-specific mortality, and a CCI of 2 or higher was associated with a significant 1.49-fold higher rate of overall mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=see_link&amp;anchor=H5#H5\">",
"     \"Comprehensive geriatric assessment for patients with cancer\", section on 'Comorbidity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Quality of life issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;QOL is a crucial component of decision-making when treating older cancer patients. The available data suggest that older patients are just as willing to try chemotherapy as their younger counterparts, but less willing to endure severe treatment-related side effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=see_link&amp;anchor=H9#H9\">",
"     \"Systemic chemotherapy for cancer in elderly persons\", section on 'Quality of life issues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Measures of physical function and reserve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronological age is a poor marker of a patient's functional status. Several methods of functional assessment are available, but there is no single valid measure that is both feasible in routine clinical practice, and can reliably predict",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    improve outcomes of older patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=see_link&amp;anchor=H24#H24\">",
"     \"Systemic chemotherapy for cancer in elderly persons\", section on 'Assessments of physical function and reserve'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Performance status &ndash; The most common method to measure physiologic reserve and functional status in cancer patients is the clinician estimated performance status (PS). There are two widely used scales, the Eastern Cooperative Oncology Group (ECOG) scale (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"       table 5",
"      </a>",
"      ) and Karnofsky Performance Status (KPS) (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 6",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PS tends to underrepresent the degree of functional impairment in the older patient. However, both the ECOG PS and KPS are useful to assess a patient's ability to tolerate chemotherapy. Regardless of age, patients with a poor PS (eg, ECOG PS &gt;2, KPS &lt;60) usually tolerate chemotherapy poorly.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ADL and IADL scales &ndash; A more comprehensive understanding of an older patient's functional state can be obtained by use of Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) scales. ADL refers to the skills that are necessary for basic living, and include feeding, grooming, transferring, and toileting. IADL refers to the skills required to live independently in the community, including shopping, managing finances, housekeeping, preparing meals, and the ability to take medications.",
"     </li>",
"     <li>",
"      Comprehensive geriatric assessment &ndash; Assessment of functional status with the ADL and IADL scales is a component of the comprehensive geriatric assessment (CGA) that is used by geriatricians to identify frail older patients at high risk of adverse outcomes such as falls, hospitalization, and death. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28792?source=see_link\">",
"       \"Frailty\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Incorporating a thorough geriatric assessment of function using the CGA can aid treatment decision-making in older cancer patients. There is no uniform CGA measurement tool, but all include some multidisciplinary assessment of the following domains: physical function, comorbid conditions, psychological state, social support, cognitive function, nutrition, and polypharmacy (",
"    <a class=\"graphic graphic_table graphicRef68620 \" href=\"UTD.htm?9/13/9436\">",
"     table 7",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Use of physical function to guide treatment decisions",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is general agreement that frail older adults, those with significant functional impairment or an ECOG PS of 3 to 4 (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"     table 5",
"    </a>",
"    ), are not appropriate candidates for chemotherapy. There is also general agreement that adjuvant chemotherapy should be offered to active, fit, older patients without comorbidity although which regimen should be used is unclear (",
"    <a class=\"graphic graphic_table graphicRef71132 \" href=\"UTD.htm?29/32/30219\">",
"     table 8",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Summary: choice of regimen'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It is the patients who are neither frail nor fit for whom treatment decision-making is most complex.",
"   </p>",
"   <p>",
"    Validated models have been developed that can be useful in predicting which patients are at increased risk of developing severe or fatal toxicity from chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/12\">",
"     12",
"    </a>",
"    ]. Parameters included within this model include age, type of cancer, the proposed chemotherapy regimen, renal and hematologic function, hearing, and activity levels from the comprehensive geriatric assessment (ability to take medications, physical activity, social activity). These parameters have been combined into a model that can be useful in predicting which patients are at increased risk of developing severe or fatal toxicity from chemotherapy (",
"    <a class=\"graphic graphic_table graphicRef78775 \" href=\"UTD.htm?17/51/18237\">",
"     table 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60649 \" href=\"UTD.htm?41/40/42636\">",
"     table 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/12\">",
"     12",
"    </a>",
"    ]. This subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=see_link&amp;anchor=H1242770806#H1242770806\">",
"     \"Systemic chemotherapy for cancer in elderly persons\", section on 'Models predicting chemotherapy toxicity and early death'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OVERVIEW OF STANDARD ADJUVANT CHEMOTHERAPY FOR COLON CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of adjuvant chemotherapy have been most clearly demonstrated in stage III (node-positive) disease, where there is an approximately 30 percent reduction in the risk of disease recurrence and a 22 to 32 percent reduction in death compared with observation alone.",
"   </p>",
"   <p>",
"    The benefit of adjuvant chemotherapy in stage II disease is more controversial. Almost all of the trials demonstrating the benefits of chemotherapy were conducted in both stage II and III disease but almost without exception, the survival benefits were limited to stage III disease. Although adjuvant chemotherapy is routinely offered to patients with higher-risk stage II disease (fewer than 13 lymph nodes in the surgical specimen, a T4 primary [(",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    )], perforation, lymphovascular or neural invasion, poorly differentiated histology), there are no data that support the view that these features identify those patients with stage II disease who might derive relatively greater benefit from adjuvant chemotherapy. In fact, at least some data from the linked Surveillance, Epidemiology and End Results",
"    <span class=\"nowrap\">",
"     (SEER)/Medicare",
"    </span>",
"    database indicate that adjuvant chemotherapy does not substantially improve overall survival in patients over the age of 65 with stage II colon cancer, with or without any of these poor prognostic features [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/13\">",
"     13",
"    </a>",
"    ]. These and other data addressing the benefit of chemotherapy for stage II disease are addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30586?source=see_link&amp;anchor=H589530323#H589530323\">",
"     \"Adjuvant chemotherapy for resected stage II colon cancer\", section on 'Benefit of fluoropyrimidine-based chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Choice of regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regimen choice is influenced by disease stage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25794326\">",
"    <span class=\"h3\">",
"     Stage III",
"    </span>",
"    &nbsp;&mdash;&nbsp;The randomized MOSAIC trial established the superiority of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    plus short-term infusional 5-FU and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (FOLFOX, (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"UTD.htm?5/20/5454\">",
"     table 11",
"    </a>",
"    )) as compared to 5-FU and leucovorin alone for adjuvant therapy of patients with stage III resected colon cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link&amp;anchor=H15#H15\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'MOSAIC trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -containing regimen such as modified FOLFOX6 (",
"    <a class=\"graphic graphic_table graphicRef50132 \" href=\"UTD.htm?16/53/17246\">",
"     table 12",
"    </a>",
"    ) is preferred for most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/14\">",
"     14",
"    </a>",
"    ], if there is a contraindication to oxaliplatin (eg, preexisting neuropathy), 5-FU plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (LV) is an option. Short-term infusional regimens of",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    (eg, the de Gramont regimen, (",
"    <a class=\"graphic graphic_table graphicRef65525 \" href=\"UTD.htm?36/17/37149\">",
"     table 13",
"    </a>",
"    )) are associated with a more favorable toxicity profile than are bolus monthly or weekly regimens, but they also require central venous access and an ambulatory infusion pump. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An alternative to",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    for patients who are not candidates for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    is six months of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    or, outside of the US, oral UFT. In randomized trials, both fluoropyrimidines have been shown to be at least as effective as bolus 5-FU and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    for adjuvant treatment of colon cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link&amp;anchor=H10#H10\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Oral fluoropyrimidines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25794341\">",
"    <span class=\"h3\">",
"     Stage II",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who choose adjuvant chemotherapy, the optimal regimen for stage II disease is controversial. As noted above, the FOLFOX regimen was superior to short-term infusional",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    in the MOSAIC trial, which was conducted in patients with both stage II and III disease. However, the survival and disease-free survival (DFS) benefit was limited to stage III disease. In an exploratory analysis there was an absolute difference in five-year DFS that favored FOLFOX in the subgroup of stage II patients with high-risk tumors, but it was not statistically significant (82 versus 75 percent, HR 0.72) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link&amp;anchor=H14#H14\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Oxaliplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In both Europe and the US, the FOLFOX regimen is approved for adjuvant therapy only for patients with stage III disease. Many oncologists routinely use",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    in this setting, and discuss FOLFOX with patients who have very high-risk stage II disease (eg, a T4 primary, (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ), lymphovascular invasion, and fewer than 12 nodes in the surgical specimen). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30586?source=see_link&amp;anchor=H589530408#H589530408\">",
"     \"Adjuvant chemotherapy for resected stage II colon cancer\", section on 'Clinicopathologic variables'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While there are no data addressing the benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    in patients with stage II disease (the randomized X-ACT trial of capecitabine versus bolus IV",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    was conducted exclusively in stage III disease), capecitabine monotherapy is a reasonable alternative to",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SAFETY AND EFFICACY OF ADJUVANT CHEMOTHERAPY IN THE ELDERLY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the significant reduction in recurrence and death associated with adjuvant chemotherapy in high-risk resected colon cancer in all populations, including the elderly, it has been used less commonly in eligible patients over age 65, particularly those over 80 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/16-27\">",
"     16-27",
"    </a>",
"    ]. However, this may be changing. In a study of over 85,000 patients with stage III colon cancer entered into the National Cancer Data Base, there was a clear trend toward increased use of adjuvant therapy for patients aged 80 and older between 1990-1991, 1995-1996, and 2001-2002 (22, 26, and 39 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individual adjuvant chemotherapy trials provide little information on chemotherapy effectiveness in the elderly because they excluded the elderly or pooled their results with those of younger patients. Yet, initial pooled subanalyses of elderly patients enrolled in clinical trials suggested that elderly patients derive as much benefit from adjuvant therapy as do younger individuals. The similar magnitude of benefit from adjuvant chemotherapy in older as compared to younger patients is supported by a pooled analysis of randomized clinical trials, a systematic review of data from both observational studies and trials in which outcomes in elderly patients were compared to those in non-elderly patients, and several population-based retrospective analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/18,21,28-33\">",
"     18,21,28-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether rates of toxic effects are higher in the elderly is less well established. While many of available studies do not indicate a clinically relevant increase in severe complications in elderly as compared to non-elderly patients, a systematic review of 25 studies of adjuvant therapy in the elderly (both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    and fluoropyrimidine-based) concluded that grade 3 or 4 adverse events were higher among elderly patients for cardiac disorders (two of five studies), neutropenia (4 of 16 studies), infection (2 of 10 studies), dehydration (two of six studies), diarrhea (6 of 20 studies), and fatigue (6 of 13 studies) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     5-FU plus leucovorin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best evidence to support the similar magnitude of benefit from adjuvant 5-FU-based chemotherapy in older as compared to younger patients comes from a pooled analysis of individual data from 3351 patients in seven randomized trials comparing adjuvant chemotherapy versus surgery alone for stage II or III colon cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/28\">",
"     28",
"    </a>",
"    ]. When patients were grouped into four age categories (&le;50, 51 to 60, 61 to 70, and &gt;70 years old), adjuvant treatment was associated with significant 24 percent reduction in mortality (overall survival 71 versus 64 percent) and a 32 percent reduction in disease recurrence that was similar in all age groups.",
"   </p>",
"   <p>",
"    The rate of toxic effects was not higher in elderly patients, with the exception of a higher rate of grade 3 or 4 neutropenia (8 versus 4 percent) in a single study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link&amp;anchor=H5#H5\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Bolus 5-FU plus LV'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42362?source=see_link\">",
"     \"Enterotoxicity of chemotherapeutic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A constraint of the pooled data is selection bias, in that presumably more fit elderly were enrolled on the individual clinical trials, and the fact that less than 1 percent of the trial participants were in their 80s. However, analysis of several population-based databases, including those of the Surveillance, Epidemiology and End Results (SEER) program of the NCI, Medicare, and the National Cancer Database, provide corroborating evidence of the benefits of adjuvant 5-FU-based chemotherapy in older adults with stage III colon cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/18,19,21,34\">",
"     18,19,21,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A survival benefit for adjuvant chemotherapy was supported by data from a population-based series of 4768 Medicare patients aged &ge;65 with stage III colon cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/18\">",
"       18",
"      </a>",
"      ]. Although it was received by only 52 percent of eligible patients, the use of 5-FU-based chemotherapy was associated with a significant 34 percent reduction in mortality.",
"     </li>",
"     <li>",
"      Likewise, data reported to the National Cancer Data Base in 2001-2002 suggest that although adjuvant chemotherapy was used less often in the elderly population (82, 77, 69 and 39 percent of patients younger than 60, 60 to 69, 70 to 79, and over age 80, respectively), the magnitude of benefit in patients with stage III disease was similar to that achieved in younger individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An analysis derived from the linked",
"      <span class=\"nowrap\">",
"       SEER/Medicare",
"      </span>",
"      database concluded that while elderly patients of all ages had a significant survival benefit associated with the receipt of adjuvant chemotherapy for stage III colon cancer, the magnitude of benefit declined with advancing age [",
"      <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Finally, data from two registry-based series suggest that up to one-third of older patients do not complete the full six month course of adjuvant chemotherapy, and that early treatment discontinuation is associated with a decline in survival [",
"      <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fewer data are available for older patients with stage II disease. However, a survival benefit for fluoropyrimidine-based adjuvant chemotherapy could not be shown in an analysis from the linked",
"    <span class=\"nowrap\">",
"     SEER/Medicare",
"    </span>",
"    database of 24,847 patients aged 65 and older who underwent colectomy for stage II colon cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the pooled analysis of data from randomized trials concluded that older patients do not necessarily have more side effects from",
"    <span class=\"nowrap\">",
"     FU/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"      leucovorin",
"     </a>",
"     ,",
"    </span>",
"    with the possible exception of myelosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/28\">",
"     28",
"    </a>",
"    ]. However, toxicity with",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    is very schedule dependent. More frequent and severe gastrointestinal toxicity (diarrhea, mucositis) is reported in elderly patients receiving bolus",
"    <span class=\"nowrap\">",
"     5-FU/LV,",
"    </span>",
"    particularly the monthly bolus Mayo regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/30,37,38\">",
"     30,37,38",
"    </a>",
"    ]. In contrast, short-term infusional regimens of",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    (the so-called de Gramont regimen) seem to be well tolerated, even in those with marginal fitness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=see_link&amp;anchor=H11#H11\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Optimizing the schedule and dose'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Oral fluoropyrimidines",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Capecitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     Capecitabine",
"    </a>",
"    is routinely used as adjuvant therapy in older patients and is reasonably well tolerated, although some studies suggest modestly higher rates of adverse effects in older as compared to younger individuals:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of patients receiving XELOX or",
"      <span class=\"nowrap\">",
"       FU/LV",
"      </span>",
"      in the adjuvant setting suggested an increase in selected adverse events, such as diarrhea and dehydration, in patients aged 65 and older compared to younger patients [",
"      <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/39\">",
"       39",
"      </a>",
"      ]. The rate of all grade 3 or 4 adverse events (65 versus 57 percent), serious adverse events (30 versus 17 percent), and withdrawals because of adverse effects (30 versus 16 percent) were also higher in the older patients, although the effect of renal function was not addressed in this study.",
"     </li>",
"     <li>",
"      In a subgroup analysis of patients over 70 treated on the X-ACT trial,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      and bolus",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      were similarly effective in older and younger patients [",
"      <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/40\">",
"       40",
"      </a>",
"      ]. Dose reduction for treatment-related toxicity was required in a higher percentage of older patients (51 versus 39 percent of those under age 70).",
"     </li>",
"     <li>",
"      A number of small elderly-specific trials in metastatic colorectal cancer have also found",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      monotherapy to be fairly well tolerated. As an example, a Spanish trial of 51 patients aged 70 or older treated with capecitabine (1250",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily for 14 of every 21 days) for metastatic colorectal cancer reported grade 3 or 4 adverse events in only six patients (12 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     Capecitabine",
"    </a>",
"    should be used with caution in the very old, particularly those with diminished renal function. In a combined analysis of data from phase III trials, a higher incidence of grade 3 or 4 adverse effects (largely diarrhea, but also hand-foot syndrome) was seen in patients &ge;80 compared to the overall population (60 versus 40 percent), particularly diarrhea (31 versus 13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/42\">",
"     42",
"    </a>",
"    ]. The specific dose of capecitabine was not given. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41466?source=see_link&amp;anchor=H14#H14\">",
"     \"Therapy for metastatic colorectal cancer in elderly patients and those with a poor performance status\", section on 'Capecitabine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approved dose is 1250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for 14 of every 21 days. However, this is often poorly tolerated in American patients, although Europeans and Asians seem to be better able to tolerate this dose. Most American oncologists start with 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily, rounding down to accommodate pill size, and titrate the dose upward as indicated by drug tolerability.",
"   </p>",
"   <p>",
"    Reimbursement policies for oral cytotoxics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    vary greatly between countries and regionally within the US. While the overall cost of therapy may be less than with parenteral",
"    <span class=\"nowrap\">",
"     5-FU/LV,",
"    </span>",
"    at least some of the cost of capecitabine is often borne by the patient. This may influence treatment choice for individual patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     UFT",
"    </span>",
"    &nbsp;&mdash;&nbsp;UFT is a 4:1 molar combination of ftorafur (Tegafur) with uracil (which competitively inhibits the degradation of 5-FU, resulting in sustained plasma and intratumoral concentrations) and LV. There are few elderly-specific data on the tolerability of UFT. In one trial in which the control arm was 39 patients over the age of 70 with resected colon cancer who received UFT alone, adverse drug reactions were rarely observed, and all were grade 2 or lower [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/43\">",
"     43",
"    </a>",
"    ]. Although UFT is widely available in Europe and Asia, it is not available in the US.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Oxaliplatin-based regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elderly patients with resected node-positive colon cancer are less likely to receive an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based regimen as compared to their younger counterparts [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/16,27\">",
"     16,27",
"    </a>",
"    ]. However, whether oxaliplatin-based chemotherapy is as effective and safe in older patients as it is in younger individuals is uncertain. The available data are conflicting. Analysis of data from several [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/15,44-46\">",
"     15,44-46",
"    </a>",
"    ] (although not all [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/47\">",
"     47",
"    </a>",
"    ]) randomized trials suggest that adding oxaliplatin to a fluoropyrimidine-based adjuvant regimen does not yield significant benefit among older patients. However, most of these trials enrolled younger healthier patients, with few over the age of 65.",
"   </p>",
"   <p>",
"    Benefit for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    in addition to adjuvant fluoropyrimidine-based chemotherapy in older patients is supported by a retrospective review of observational databases across a diverse array of practice settings, including the linked SEER-Medicare database [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/48\">",
"     48",
"    </a>",
"    ]. The following represents the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Results from the MOSAIC trial (short-term-infusional",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      with and without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      ) and NSABP C-07 (bolus weekly FU and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      with and without oxaliplatin) cast doubt as to the benefit of oxaliplatin in the elderly [",
"      <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]. In subgroup analyses of both trials, the significant disease-free survival benefit of adding oxaliplatin was present only in patients under age 70.",
"     </li>",
"     <li>",
"      The benefit of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      in patients aged 70 and older was also called into question by an analysis of data from the ACCENT database that was presented at the 2009 meeting of the American Society of Clinical Oncology (ASCO) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/46\">",
"       46",
"      </a>",
"      ]. Of the &gt;12,500 patients enrolled in randomized trials comparing IV 5-FU to combinations that contained",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      , oxaliplatin, or oral fluoropyrimidines, 2170 were 70 years of age or older. In the preliminary report, overall survival, DFS, and time to tumor recurrence were significantly better for oxaliplatin-based therapy in individuals under the age of 70 (HR 0.81 in favor of newer therapies) but not in older patients (HR 1.04).",
"      <br/>",
"      <br/>",
"      It is difficult to know how to interpret these data. The analysis did not consider issues related to toxicity or competing risk of death from non-colon cancer causes. The finding of a trend toward a higher risk of death within six months of starting therapy in older individuals receiving oxaliplatin (2.6 versus 1.4 percent) suggests that patient selection is a key factor. Death from non-colorectal causes, and dose reductions",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      delays may largely explain the observed differences between older and younger patients.",
"     </li>",
"     <li>",
"      On the other hand, a survival benefit for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      in older patients and those with higher levels of comorbidity was supported by an analysis of five observational database cohorts (the largest of which was the linked SEER-Medicare database), altogether totaling 4060 patients who were treated for stage III colon cancer at the community level in diverse practice settings between 2004 and 2009 [",
"      <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/48\">",
"       48",
"      </a>",
"      ]. Compared to the survival benefit seen with the use of oxaliplatin in five randomized controlled trials with a fluoropyrimidine-alone control arm (hazard ratio for death at three years 0.80, 95% CI 0.70-0.92; three-year overall survival 86 versus 82 percent), three-year survival of the oxaliplatin-treated patients was remarkably similar in the database cohorts. Furthermore, after adjusting for differences in patient and tumor characteristics between treatment arms, the survival HR point estimates of all of the retrospective cohorts showed at least as much reduction in death rates with the addition of oxaliplatin as did the randomized trial analysis although the effect was statistically significant in only two of the cohorts, including SEER-Medicare.",
"      <br/>",
"      <br/>",
"      The benefit of oxaliplatin was maintained across all clinically relevant patient subgroups although small sample size limited the precision of the hazard ratio estimates. As an example, oxaliplatin-treated patients aged 70 to 74 had significantly improved survival in the SEER-Medicare database (HR for death 0.66, 95% CI 0.52-0.84) but not in others. Benefit for oxaliplatin was also evident in patients with a Carlson Comorbidity Index of 2, although in four of the five cohorts, the benefit was not statistically significant. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Comorbid conditions'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In a later similar analysis of data from four of the observational cohorts (including Medicare-SEER) that was limited to patients over the age of 75, the incremental benefit of oxaliplatin over non-oxaliplatin-based regimens was even less clear, with a nonstatistically significant difference in outcomes (HR for death 0.84, 95% CI 0.69-1.04) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/32\">",
"       32",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      The relative toxicity of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      versus non-oxaliplatin-containing adjuvant chemotherapy in elderly patients was addressed in a separate retrospective analysis of data from the linked",
"      <span class=\"nowrap\">",
"       SEER/Medicare,",
"      </span>",
"      New York State Cancer Registry",
"      <span class=\"nowrap\">",
"       (NYSCR)/Medicare,",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       NYSCR/Medicaid",
"      </span>",
"      databases [",
"      <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/51\">",
"       51",
"      </a>",
"      ]. There was evidence of a trend toward more adverse events with oxaliplatin as compared to fluoropyrimidine use with advancing age (odds ratios for age 65-69, 70-74, 75-79, 80-84 and &ge;85 years were 1.67, 3.18, 1.8, 3.37, and 3.18, respectively). However, the incremental harms were modest and limited to outpatient adverse events. Among patients 75 and older, rates of neutropenia (OR 17.3, 95% CI 9.80-30.42) and nausea and vomiting (OR 2.14, 95% CI 1.73-2.65), but not diarrhea and dehydration were significantly higher with oxaliplatin versus fluoropyrimidine alone treatment. Rates of emergency department use, hospitalization, or early death were not higher in those who received oxaliplatin as compared to a fluoropyrimidine alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, questions remain as to the survival benefit of adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    to a 5-FU-based adjuvant chemotherapy regimen in the elderly. Nevertheless, for fit elderly with stage III disease, the risks and potential benefits of an oxaliplatin-based chemotherapy regimen should be discussed. Clinicians should consider carefully whether older patients are sufficiently robust to tolerate treatment-related toxicity and have an estimated life expectancy of at least five years before recommending the use of oxaliplatin. For patients who are reasonable candidates for oxaliplatin, and who have an estimated life expectancy of at least five years, we suggest oxaliplatin-based chemotherapy rather than",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    monotherapy. The use of 5-FU plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    remains a reasonable alternative to an oxaliplatin-based regimen for adjuvant treatment of stage III disease in the elderly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Irinotecan-based regimens, bevacizumab, and cetuximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     Irinotecan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    have not proven beneficial in the adjuvant setting in randomized trials, and their use is not recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link&amp;anchor=H19#H19\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Irinotecan'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link&amp;anchor=H21#H21\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Bevacizumab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link&amp;anchor=H23#H23\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Cetuximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Summary: choice of regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal regimen for elderly patients who require adjuvant chemotherapy for high-risk colon cancer is uncertain. For fit older patients with stage III disease, we discuss the benefits and risks of an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based regimen versus",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    alone. Clinicians should consider carefully whether older patients are sufficiently robust to tolerate treatment-related toxicity and have an estimated life expectancy of at least five years before recommending the use of oxaliplatin.",
"   </p>",
"   <p>",
"    If an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based regimen is chosen, we prefer modified FOLFOX6 (",
"    <a class=\"graphic graphic_table graphicRef50132 \" href=\"UTD.htm?16/53/17246\">",
"     table 12",
"    </a>",
"    ). Omission of the 5-FU bolus (ie, modified FOLFOX7, (",
"    <a class=\"graphic graphic_table graphicRef55829 \" href=\"UTD.htm?10/19/10558\">",
"     table 14",
"    </a>",
"    )) may be necessary because of neutropenia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombocytopenia persisting until the subsequent cycle. If ambulatory infusion pump therapy is not feasible,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    plus oxaliplatin (XELOX, (",
"    <a class=\"graphic graphic_table graphicRef61781 \" href=\"UTD.htm?13/60/14286\">",
"     table 15",
"    </a>",
"    )) is a reasonable alternative, but appropriate dosing for elderly patients remains an area of uncertainty. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In less fit older patients with stage III disease and for those with high-risk stage II disease who choose adjuvant therapy, we use",
"    <span class=\"nowrap\">",
"     FU/LV",
"    </span>",
"    rather than an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based regimen. Rather than the original de Gramont regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/52\">",
"     52",
"    </a>",
"    ], we prefer a modified short-term infusional schedule (",
"    <a class=\"graphic graphic_table graphicRef65525 \" href=\"UTD.htm?36/17/37149\">",
"     table 13",
"    </a>",
"    ) that eliminates the day 2 bolus doses of 5-FU and LV as it is very well tolerated, even in those of marginal fitness. If well tolerated, oxaliplatin could be added to later cycles for patients with stage III disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    is a reasonable option for older patients who are unlikely to tolerate combination therapy and who clearly understand how to take the medicine and what to do in the event of an adverse reaction. The appropriate capecitabine dose is unclear. Most American oncologists start at 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily, and titrate the dose upward as tolerated. Out of pocket expense issues may influence the use of capecitabine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23557872\">",
"    <span class=\"h3\">",
"     Chemotherapy dosing in obese patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;For cancer patients with a large body surface area (BSA), chemotherapy drug doses are often reduced, because of concern for excess toxicity. However, there is no evidence that fully-dosed obese patients experience greater toxicity from chemotherapy for colorectal cancer; furthermore, at least in the setting of advanced disease, obese patients who are given reduced doses may have inferior outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/53\">",
"     53",
"    </a>",
"    ]. Guidelines from ASCO recommend that full weight-based cytotoxic chemotherapy doses be used to treat obese patients with cancer, particularly when the goal of treatment is cure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21572705\">",
"    <span class=\"h2\">",
"     Use of web-based tools for assessing prognosis and benefit from adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to select a patient for adjuvant therapy can be challenging, particularly for elderly patients who are neither frail nor fit. Web-based calculators such as Adjuvant! Online [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/55\">",
"     55",
"    </a>",
"    ] can quantify outcomes with and without adjuvant therapy, and they incorporate life expectancy for a given patient's age and gender, and an estimate of the burden of comorbid disease.",
"   </p>",
"   <p>",
"    While tools such as Adjuvant! Online can provide a useful adjunct to aid in the discussion of risks and benefits from adjuvant chemotherapy for individual patients, they need to be interpreted in the context of physiologic age. Furthermore, they are not a substitute for sound physician judgment. The decision to pursue treatment requires careful consideration of all aspects of the individual patient by the clinician, including those that are not contained in Adjuvant! Online or Numeracy (eg, perforation).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/27/19890?source=see_link\">",
"       \"Patient information: Colon and rectal cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/0/6148?source=see_link\">",
"       \"Patient information: Colon and rectal cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/22/40293?source=see_link\">",
"       \"Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older patients derive as much benefit from 5-FU-based adjuvant chemotherapy as do younger patients, although the incremental benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    may be less. While pooled analyses point to a modest increase in the rate of severe hematologic toxicity in the fit elderly who have been accrued to studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/28,44\">",
"     28,44",
"    </a>",
"    ], other toxicities are not necessarily worse when close attention is paid to regimen selection.",
"   </p>",
"   <p>",
"    We routinely recommend adjuvant chemotherapy for fit older patients with stage III and high-risk stage II colon cancer, and we discuss the risks and benefits of chemotherapy with non-fit but non-frail elderly patients. Given their poor tolerance for therapy and limited life expectancy, frail older adults, those with significant functional impairment or an ECOG PS of 3 to 4 (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"     table 5",
"    </a>",
"    ), are not appropriate candidates for adjuvant chemotherapy. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Use of physical function to guide treatment decisions'",
"    </a>",
"    above.) In elderly patients with high risk stage II colon cancer, a discussion of the risks of therapy in light of&nbsp;what is certainly no more than a small potential benefit must be conducted while considering&nbsp;the&nbsp;patient's individual preferences and values.&nbsp;",
"   </p>",
"   <p>",
"    A comprehensive geriatric assessment may be useful to determine whether or not a patient is a candidate for adjuvant treatment and in formulating an appropriate, individualized treatment plan. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of a web-based tool such as Adjuvant! online can serve as an adjunct to aid discussions on the risks and potential benefits of adjuvant chemotherapy with individual patients, but tools such as these cannot replace a comprehensive geriatric assessment, sound physician judgment, or patient choice. (See",
"    <a class=\"local\" href=\"#H21572705\">",
"     'Use of web-based tools for assessing prognosis and benefit from adjuvant therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For fit patients with stage III disease, we suggest discussing the risks and potential benefits of an",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -based chemotherapy regimen. For patients who are reasonable candidates for oxaliplatin, and who have an estimated life expectancy of at least five years, we suggest oxaliplatin-based chemotherapy rather than",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      monotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, given the uncertainty as to the overall survival benefit for oxaliplatin-based regimens in the elderly, a reasonable alternative is",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      or single agent capecitabine.",
"      <br/>",
"      <br/>",
"      If an oxaliplatin regimen is chosen, we prefer the modified FOLFOX6 regimen in this population (",
"      <a class=\"graphic graphic_table graphicRef50132 \" href=\"UTD.htm?16/53/17246\">",
"       table 12",
"      </a>",
"      ). Given the added risk of significant myelosuppression in the elderly, an alternative is FOLFOX with omission of the 5-FU bolus (ie, modified FOLFOX7, (",
"      <a class=\"graphic graphic_table graphicRef55829 \" href=\"UTD.htm?10/19/10558\">",
"       table 14",
"      </a>",
"      )). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Summary: choice of regimen'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10963?source=see_link\">",
"       \"Treatment protocols for colorectal cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      For patients in whom therapy with an ambulatory infusion pump is not feasible, capecitabine plus oxaliplatin (XELOX, (",
"      <a class=\"graphic graphic_table graphicRef61781 \" href=\"UTD.htm?13/60/14286\">",
"       table 15",
"      </a>",
"      )) is a reasonable alternative [",
"      <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/47\">",
"       47",
"      </a>",
"      ]. However, if XELOX is chosen, we would suggest beginning therapy with a smaller dose of capecitabine than was used in the NO16968 trial (825",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily) and escalate to 1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily only as tolerated. Capecitabine also requires dose reduction in patients with renal function impairment. &nbsp;",
"     </li>",
"     <li>",
"      For less fit individuals with stage III disease who are deemed less likely to tolerate",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      , or who have comorbid conditions that are likely to limit their five-year survival, and those with high-risk stage II disease, we suggest",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      or single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      rather than FOLFOX (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      When",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      -modulated 5-FU is chosen, we prefer a modified short-term infusional schedule of",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef65525 \" href=\"UTD.htm?36/17/37149\">",
"       table 13",
"      </a>",
"      ) rather than the original de Gramont schedule [",
"      <a class=\"abstract\" href=\"UTD.htm?10/51/11066/abstract/52\">",
"       52",
"      </a>",
"      ] because it eliminates the requirement for a day 2 bolus, is more convenient, and very well tolerated, even in those of marginal fitness. (See",
"      <a class=\"local\" href=\"#H12\">",
"       '5-FU plus leucovorin'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10963?source=see_link\">",
"       \"Treatment protocols for colorectal cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Single agent capecitabine is a reasonable alternative to leucovorin-modulated 5-FU, particularly if ambulatory infusion therapy is not feasible. We suggest starting with 1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily for 14 of every 21 days, and titrating the dose upward as indicated by treatment tolerability. Capecitabine requires dose reduction in patients with renal function impairment. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Capecitabine'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Use of capecitabine should be limited to individuals who clearly understand how to take the medicine and what to do in the event of an adverse reaction. Reimbursement issues may influence the choice of an oral fluoropyrimidine.",
"     </li>",
"     <li>",
"      We recommend not using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ) or an",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      -based regimen (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ) in the adjuvant setting for any age group. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Irinotecan-based regimens, bevacizumab, and cetuximab'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     Ries L, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD. file://seer.cancer.gov/csr/1975_2006/ (Accessed on March 14, 2011).",
"    </li>",
"    <li>",
"     US Interim Projections by Age, Sex, Race, and Hispanic Origin. US Census Burreau, 2004.",
"    </li>",
"    <li>",
"     AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th edition, Edge, SB, Byrd, DR, Compton, CC, et al (Eds) (Eds), Springer, New York 2010. p.143.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/5\">",
"      Sawhney R, Sehl M, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J 2005; 11:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/6\">",
"      Sehl M, Sawhney R, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part II. Cancer J 2005; 11:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/7\">",
"      Yancik R, Wesley MN, Ries LA, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer 1998; 82:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/8\">",
"      Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24:3187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/9\">",
"      Yancik R, Ries LA. Cancer in older persons. Magnitude of the problem--how do we apply what we know? Cancer 1994; 74:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/10\">",
"      Gross CP, McAvay GJ, Guo Z, Tinetti ME. The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. Cancer 2007; 109:2410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/11\">",
"      Hines RB, Chatla C, Bumpers HL, et al. Predictive capacity of three comorbidity indices in estimating mortality after surgery for colon cancer. J Clin Oncol 2009; 27:4339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/12\">",
"      Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011; 29:3457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/13\">",
"      O'Connor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 2011; 29:3381.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/15\">",
"      Andr&eacute; T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27:3109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/16\">",
"      Kahn KL, Adams JL, Weeks JC, et al. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA 2010; 303:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/17\">",
"      Potosky AL, Harlan LC, Kaplan RS, et al. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 2002; 20:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/18\">",
"      Sundararajan V, Mitra N, Jacobson JS, et al. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 2002; 136:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/19\">",
"      Iwashyna TJ, Lamont EB. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol 2002; 20:3992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/20\">",
"      Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001; 93:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/21\">",
"      Jessup JM, Stewart A, Greene FL, Minsky BD. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 2005; 294:2703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/22\">",
"      Bradley CJ, Given CW, Dahman B, Fitzgerald TL. Adjuvant chemotherapy after resection in elderly Medicare and Medicaid patients with colon cancer. Arch Intern Med 2008; 168:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/23\">",
"      Keating NL, Landrum MB, Klabunde CN, et al. Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? J Clin Oncol 2008; 26:2532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/24\">",
"      Ananda S, Field KM, Kosmider S, et al. Patient age and comorbidity are major determinants of adjuvant chemotherapy use for stage III colon cancer in routine clinical practice. J Clin Oncol 2008; 26:4516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/25\">",
"      Etzioni DA, El-Khoueiry AB, Beart RW Jr. Rates and predictors of chemotherapy use for stage III colon cancer: a systematic review. Cancer 2008; 113:3279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/26\">",
"      Hynes DM, Tarlov E, Durazo-Arvizu R, et al. Surgery and adjuvant chemotherapy use among veterans with colon cancer: insights from a California study. J Clin Oncol 2010; 28:2571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/27\">",
"      Abrams TA, Brightly R, Mao J, et al. Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer. J Clin Oncol 2011; 29:3255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/28\">",
"      Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/29\">",
"      Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/30\">",
"      Popescu RA, Norman A, Ross PJ, et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999; 17:2412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/31\">",
"      Feliu J, Escudero P, Llosa F, et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Clin Oncol 2005; 23:3104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/32\">",
"      Sanoff HK, Carpenter WR, St&uuml;rmer T, et al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol 2012; 30:2624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/33\">",
"      Hung A, Mullins CD. Relative effectiveness and safety of chemotherapy in elderly and nonelderly patients with stage III colon cancer: a systematic review. Oncologist 2013; 18:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/34\">",
"      Zuckerman IH, Rapp T, Onukwugha E, et al. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer. J Am Geriatr Soc 2009; 57:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/35\">",
"      Dobie SA, Baldwin LM, Dominitz JA, et al. Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst 2006; 98:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/36\">",
"      Neugut AI, Matasar M, Wang X, et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol 2006; 24:2368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/37\">",
"      Stein BN, Petrelli NJ, Douglass HO, et al. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995; 75:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/38\">",
"      Zalcberg J, Kerr D, Seymour L, Palmer M. Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. Eur J Cancer 1998; 34:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/39\">",
"      Schmoll HJ, Cartwright T, Tabernero J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007; 25:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/40\">",
"      Twelves C, Scheithauer W, McKendrick J, et al. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol 2012; 23:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/41\">",
"      Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007; 25:1824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/42\">",
"      Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/43\">",
"      Yoshitani S, Takashima S. Efficacy of postoperative UFT (Tegafur/Uracil) plus PSK therapies in elderly patients with resected colorectal cancer. Cancer Biother Radiopharm 2009; 24:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/44\">",
"      Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24:4085.",
"     </a>",
"    </li>",
"    <li>",
"     Haller DG, Cassidy J, Tabernero J, et al. Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): No impact of age on disease-free survival (abstract). Data presented at the 2010 ASCO Gastrointestinal Cancers Symposium, Orlando, FL, January 22, 2010.",
"    </li>",
"    <li>",
"     Jackson McCleary NA, Meyerhardt J, Green E, et al. Impact of older age on the efficacy of newer adjuvant therapies in &gt;12,500 patients with stage II/III colon cancer: Finedings from the ACCENT database (abstract #4010). J Clin Oncol 2009; 27:170s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/47\">",
"      Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011; 29:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/48\">",
"      Sanoff HK, Carpenter WR, Martin CF, et al. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst 2012; 104:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/49\">",
"      Yothers G, O'Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011; 29:3768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/50\">",
"      Tournigand C, Andr&eacute; T, Bonnetain F, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 2012; 30:3353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/51\">",
"      Sanoff HK, Carpenter WR, Freburger J, et al. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis. Cancer 2012; 118:4309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/52\">",
"      de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/53\">",
"      Chambers P, Daniels SH, Thompson LC, Stephens RJ. Chemotherapy dose reductions in obese patients with colorectal cancer. Ann Oncol 2012; 23:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/51/11066/abstract/54\">",
"      Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012; 30:1553.",
"     </a>",
"    </li>",
"    <li>",
"     Adjuvant! Online. www.adjuvantonline.com (Accessed on September 01, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2508 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-4563C940AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_51_11066=[""].join("\n");
var outline_f10_51_11066=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHALLENGES SPECIFIC TO THE ELDERLY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Age-related organ function decline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Comorbid conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Quality of life issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Measures of physical function and reserve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Use of physical function to guide treatment decisions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OVERVIEW OF STANDARD ADJUVANT CHEMOTHERAPY FOR COLON CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Choice of regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25794326\">",
"      - Stage III",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25794341\">",
"      - Stage II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SAFETY AND EFFICACY OF ADJUVANT CHEMOTHERAPY IN THE ELDERLY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      5-FU plus leucovorin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Oral fluoropyrimidines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Capecitabine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - UFT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Oxaliplatin-based regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Irinotecan-based regimens, bevacizumab, and cetuximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Summary: choice of regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23557872\">",
"      - Chemotherapy dosing in obese patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21572705\">",
"      Use of web-based tools for assessing prognosis and benefit from adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2508\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2508|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/1/12318\" title=\"figure 1\">",
"      SEER CRC incid mort",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/54/41824\" title=\"figure 2\">",
"      SEER surv adeno colon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2508|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/26/23982\" title=\"table 1\">",
"      2010 TNM staging colorectal CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/61/22491\" title=\"table 2\">",
"      Organ function change age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/63/39932\" title=\"table 3\">",
"      Life exp CRC stage III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/40/26252\" title=\"table 4\">",
"      Charlson risk index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 5\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 6\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/13/9436\" title=\"table 7\">",
"      Elements comp geri assess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/32/30219\" title=\"table 8\">",
"      CRC chemo elderly guide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/51/18237\" title=\"table 9\">",
"      Model for predicting chemotherapy toxicity in older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/40/42636\" title=\"table 10\">",
"      Risk score versus physician-rated KPS chemo toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/20/5454\" title=\"table 11\">",
"      Chemo regimens met CRC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/53/17246\" title=\"table 12\">",
"      Modified FOLFOX6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/17/37149\" title=\"table 13\">",
"      Modified de Gramont schedule for gastrointestinal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/19/10558\" title=\"table 14\">",
"      Modified FOLFOX7 regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/60/14286\" title=\"table 15\">",
"      XELOX regimen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30586?source=related_link\">",
"      Adjuvant chemotherapy for resected stage II colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4922?source=related_link\">",
"      Adjuvant therapy for resected rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=related_link\">",
"      Adjuvant therapy for resected stage III (node-positive) colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42362?source=related_link\">",
"      Enterotoxicity of chemotherapeutic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28792?source=related_link\">",
"      Frailty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30489?source=related_link\">",
"      Overview of the management of primary colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/0/6148?source=related_link\">",
"      Patient information: Colon and rectal cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/27/19890?source=related_link\">",
"      Patient information: Colon and rectal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/22/40293?source=related_link\">",
"      Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28634?source=related_link\">",
"      Surveillance after colorectal cancer resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=related_link\">",
"      Systemic chemotherapy for cancer in elderly persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41466?source=related_link\">",
"      Therapy for metastatic colorectal cancer in elderly patients and those with a poor performance status",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10963?source=related_link\">",
"      Treatment protocols for colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=related_link\">",
"      Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_51_11067="Pathogens following BMT-II";
var content_f10_51_11067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pathogens likely to cause infections in bone marrow/stem cell transplant recipients not receiving standard prophylaxis-II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Immediate post-engraftment (3 weeks to 3 months)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Bacteria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Same as for the pre-engraftment period",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Fungi",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Aspergillus spp.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Viruses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Cytomegalovirus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       HHV-6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Respiratory viruses (Same as for the pre-engraftment period) &gt;3 mos",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Protozoa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Pneumocystis carinii",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_51_11067=[""].join("\n");
var outline_f10_51_11067=null;
var title_f10_51_11068="Indications TTO2";
var content_f10_51_11068=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential benefits and indications for transtracheal oxygen",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Potential benefits compared to standard nasal cannula",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Improved compliance with 24 hr/day oxygen use",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Eliminate tenderness and irritation caused by the nasal cannula",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Decreased oxygen flow requirement, greater portability",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Less dyspnea, improved exercise endurance",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cosmetically more acceptable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Adequate oxygenation despite refractory baseline hypoxemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Specific indications",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Suboptimal compliance or oxygenation with nasal cannula delivery",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Complications caused by the nasal cannula",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Desire for greater mobility",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Patient preference",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Refractory hypoxemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nocturnal hypoxemia despite nasal cannula",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Ideal candidate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Low nasal cannula flow requirement (1 to 4 L/min)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Strong desire to remain active (eg, spend less than 12 hours per day in bed and leave house routinely for shopping, socializing, or work)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Willing and able to follow care protocol",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Disease process \"stable\"",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Demonstrates good adherence to medical regimen",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Additional important considerations",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Care partner willing to be part of the team or close support from significant other",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lives within one hour of institution, or equivalent follow up available elsewhere",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Has dependable transportation",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_51_11068=[""].join("\n");
var outline_f10_51_11068=null;
var title_f10_51_11069="Sickle cell diagnostic test";
var content_f10_51_11069=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic testing for the common sickle cell syndromes*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Syndrome",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Neonatal screening&Delta;",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Hemoglobin separation by age 6 weeks&Delta;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Hemoglobin separation in older children (&ge;5 yr)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Hb A (percent)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Hb S (percent)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Hb F (percent)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Hb A",
"        <sub>",
"         2",
"        </sub>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Hb C (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sickle cell anemia (HbSS)",
"       </td>",
"       <td>",
"        FS",
"       </td>",
"       <td>",
"        FS",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        75-95",
"       </td>",
"       <td>",
"        2-25&sect;",
"       </td>",
"       <td>",
"        &lt;3.5",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sickle &beta;&deg;-thalassemia&bull;",
"       </td>",
"       <td>",
"        FS",
"       </td>",
"       <td>",
"        FS",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        80-92",
"       </td>",
"       <td>",
"        2-15",
"       </td>",
"       <td>",
"        3.5-7.0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sickle-hemoglobin C disease (Hb SC)",
"       </td>",
"       <td>",
"        FSC",
"       </td>",
"       <td>",
"        FSC",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        45-50",
"       </td>",
"       <td>",
"        1-5",
"       </td>",
"       <td>",
"        NA&yen;",
"       </td>",
"       <td>",
"        45-50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sickle &beta;",
"        <sup>",
"         +",
"        </sup>",
"        -thalassemia&bull;",
"       </td>",
"       <td>",
"        FSA or FS&loz;",
"       </td>",
"       <td>",
"        FSA",
"       </td>",
"       <td>",
"        5-30",
"       </td>",
"       <td>",
"        65-90",
"       </td>",
"       <td>",
"        2-10",
"       </td>",
"       <td>",
"        3.5-6.0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sickle cell trait",
"       </td>",
"       <td>",
"        FAS",
"       </td>",
"       <td>",
"        FAS",
"       </td>",
"       <td>",
"        50-60",
"       </td>",
"       <td>",
"        35-45",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        &lt;3.5",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        FA",
"       </td>",
"       <td>",
"        FA or AF",
"       </td>",
"       <td>",
"        95-98",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        &lt;3.5",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Table shows results of hemoglobin separation tests (i.e. hemoglobin electrophoresis, isoelectric focusing and/or HPLC). In selected cases DNA analysis or testing of parents may be helpful.",
"     <br>",
"      &bull; &beta;&deg; indicates thalassemia mutation with absent production of &beta;-globin (i.e. no Hb A); &beta;",
"      <sup>",
"       +",
"      </sup>",
"      indicates thalassemia mutation with reduced (but not absent) production of &beta;-globin.",
"      <br>",
"       &Delta; Hemoglobins reported in order of quantity (e.g. FSA=F&gt;S&gt;A); F: fetal hemoglobin; S: sickle hemoglobin; C: hemoglobin C; A: hemoglobin A. Abnormal results require confirmation with Hb electrophoresis, isolectric focusing, HPLC, and/or DNA studies.",
"       <br>",
"        &loz; Quantity of Hb A at birth sometimes insufficient for detection.",
"        <br>",
"         &sect; Hb F levels in rare cases of Hb SS may be high enough to cause confusion with Hb S-pancellular Hereditary Persistence of Fetal Hemoglobin (S-HPFH), a benign disorder not usually associated with significant anemia or vaso-occlusion. In such cases family studies and laboratory tests to evaluate the distribution of Hb F among red cells may be helpful.",
"         <br>",
"          &yen; Quantity of Hb A",
"          <sub>",
"           2",
"          </sub>",
"          cannot be measured by electrophoresis in presence of Hb C.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sickle cell disease in children and adolescents: Diagnosis, guidelines for comprehensive care, and care paths and protocols for management of acute and chronic complications. Revised at the Annual Meeting of the Sickle Cell Disease Care Consortium, Sedona, AZ, November 10-12, 2001.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_51_11069=[""].join("\n");
var outline_f10_51_11069=null;
var title_f10_51_11070="Pathogenesis of RPC";
var content_f10_51_11070=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F70792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F70792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypothetical schema of pathogenesis of relapsing polychondritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 270px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_51_11070=[""].join("\n");
var outline_f10_51_11070=null;
var title_f10_51_11071="Dilation esophageal stricture";
var content_f10_51_11071=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Dilation of esophageal stricture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 149px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel 1: Endoscopic appearance of an esophageal stricture with a very small opening from the esophagus into the stomach. The whitish areas radiating proximally up the esophagus are linear erosions. Biopsies in this area disclose active esophagitis. Panel 2: A balloon dilator is positioned within the stricture and the balloon was inflated. Panel 3: The stricture is dilated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_51_11071=[""].join("\n");
var outline_f10_51_11071=null;
